Hyoung Jung Kim, Presenter: Nothing to Disclose

Moon-Gyu Lee MD, Abstract Co-Author: Nothing to Disclose

Kyung Won Kim, Abstract Co-Author: Nothing to Disclose

Hyung Jin Won MD, Abstract Co-Author: Nothing to Disclose

Jae Ho Byun MD, Abstract Co-Author: Nothing to Disclose

Ah Young Kim MD, Abstract Co-Author: Nothing to Disclose

Yong Moon Shin MD, Abstract Co-Author: Nothing to Disclose

Pyo Nyun Kim MD, Abstract Co-Author: Nothing to Disclose

Hyun Kwon Ha MD, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

To compare hepatic lesion detection and characterization of colorectal cancer patients on mangafodipir trisodium-enhanced and ferucarbotran-enhanced MR imaging.

Consecutive 41 patients suspected of hepatic metastasis from colorectal cancer, underwent mangafodipir trisodium- or ferucarbotran- enhanced MR imaging in block randomization and prospective methods. Eighty-two hepatic lesions (53 metastases and 29 benign lesions) were included in the study. Two radiologists independently reviewed MR imaging to determine the number of hepatic lesions and lesion characterization as to be benign or metastatic. The differences in lesion detection and in distinguishing metastases were analyzed according to lesion size (small, ≤ 2.0 cm; large, > 2 cm in diameter) on both MR Imaging. The interpretation data from two observers were correlated with the reference diagnosis: histopathology or intraoperative ultrasonography in 47 hepatic lesions; and follow-up imaging (> 3 months) in 35 ones. The performance of both MR Imaging in determining the metastases was assessed using receiver operating characteristic curves.

There were of no significant differences between mangafodipir trisodium-enhanced and ferucarbotran-enhanced MR imaging in detecting all hepatic lesions (p=.183), small hepatic lesions (p=.299), all metastases (p =.695), and small metastases (p =.689). The Az (area under the curve) values of individual observers on both MR imaging, showed no significant difference as well in distinguishing metastases from benign lesions.

Our study shows similar results in hepatic lesion detection and characterization in colorectal cancer patients on Mangafodipir trisodium- and ferucarbotran-enhanced MR imaging.

Kim, H, Lee, M, Kim, K, Won, H, Byun, J, Kim, A, Shin, Y, Kim, P, Ha, H, et al, , Hepatic Metastasis in Colorectal Cancer Patients: Detection and Characterization between Mangafodipir Trisodium-enhanced and Ferucarbotran-enhanced MR Imaging.  Radiological Society of North America 2004 Scientific Assembly and Annual Meeting, November 28 - December 3, 2004 ,Chicago IL. http://archive.rsna.org/2004/4411265.html